GRANDE PHARMACIE REGIONALE KUYPERS : revenue, balance sheet and financial ratios

GRANDE PHARMACIE REGIONALE KUYPERS is a French company founded 14 years ago, specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé. Based in SULLY-SUR-LOIRE (45600), this company of category PME shows in 2022 a revenue of 2.0 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - GRANDE PHARMACIE REGIONALE KUYPERS (SIREN 538237710)
Indicator 2025 2024 2023 2022 2021 2020 2019
Revenue N/C N/C N/C 1 997 935 € 1 884 635 € 1 911 929 € 2 017 248 €
Net income 89 845 € 64 173 € 77 828 € 120 548 € 112 147 € 87 740 € 50 318 €
EBITDA N/C N/C N/C 149 174 € 143 834 € 114 699 € 59 506 €
Net margin N/C N/C N/C 6.0% 6.0% 4.6% 2.5%

Revenue and income statement

In 2025, GRANDE PHARMACIE REGIONALE KUYPERS generates positive net income of 90 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2019-2025: 50 k€ -> 90 k€.

Net income (2025) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

89 845 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 25%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 76%. This high autonomy means the company finances most of its assets through equity, a sign of strength.

Debt ratio (2025) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

24.922%

Financial autonomy (2025) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

75.503%

Asset age ratio (2025) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

15.8%

Solvency indicators evolution
GRANDE PHARMACIE REGIONALE KUYPERS

Sector positioning

Debt ratio
24.92 2025
2023
2024
2025
Q1: 13.7
Med: 49.79
Q3: 129.09
Good +8 pts over 3 years

In 2025, the debt ratio of GRANDE PHARMACIE REGIONAL... (24.92) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.

Financial autonomy
75.5% 2025
2023
2024
2025
Q1: 33.42%
Med: 53.72%
Q3: 72.08%
Excellent

In 2025, the financial autonomy of GRANDE PHARMACIE REGIONAL... (75.5%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 374.81. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2025) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

374.806

Liquidity indicators evolution
GRANDE PHARMACIE REGIONALE KUYPERS

Sector positioning

Liquidity ratio
374.81 2025
2023
2024
2025
Q1: 131.03
Med: 182.25
Q3: 258.64
Excellent

In 2025, the liquidity ratio of GRANDE PHARMACIE REGIONAL... (374.81) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.

Operating WCR (2025) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2025) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

0 j

Supplier credit (2025) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

0 j

Inventory turnover (2025) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
GRANDE PHARMACIE REGIONALE KUYPERS

Positioning of GRANDE PHARMACIE REGIONALE KUYPERS in its sector

Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé

Valuation estimate

Based on 277 transactions of similar company sales in 2025, the value of GRANDE PHARMACIE REGIONALE KUYPERS is estimated at 1 427 198 € (range 968 503€ - 2 239 470€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2025
277 transactions
968k€ 1427k€ 2239k€
1 427 198 € Range: 968 503€ - 2 239 470€
NAF 5 année 2025

Valuation method used

Net Income Multiple
89 845 € × 15.9x = 1 427 199 €
Range: 968 504€ - 2 239 471€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)

Compare GRANDE PHARMACIE REGIONALE KUYPERS with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de détail de produits pharmaceutiques en magasin spécialisé

Frequently asked questions about GRANDE PHARMACIE REGIONALE KUYPERS

What is the revenue of GRANDE PHARMACIE REGIONALE KUYPERS ?

The revenue of GRANDE PHARMACIE REGIONALE KUYPERS in 2022 is 2.0 M€.

Is GRANDE PHARMACIE REGIONALE KUYPERS profitable?

Yes, GRANDE PHARMACIE REGIONALE KUYPERS generated a net profit of 90 k€ in 2025.

Where is the headquarters of GRANDE PHARMACIE REGIONALE KUYPERS ?

The headquarters of GRANDE PHARMACIE REGIONALE KUYPERS is located in SULLY-SUR-LOIRE (45600), in the department Loiret.

Where to find the tax return of GRANDE PHARMACIE REGIONALE KUYPERS ?

The tax return of GRANDE PHARMACIE REGIONALE KUYPERS is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does GRANDE PHARMACIE REGIONALE KUYPERS operate?

GRANDE PHARMACIE REGIONALE KUYPERS operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.